No association between proton pump inhibitor use and dementia risk: data
mining of US Food and Drug Administration adverse event reporting system
AIM: Proton pump inhibitors (PPIs) were widely used around the world.
Studies suggested conflicting results between PPIs treatment and the
risk of dementia. This study examined the association between PPIs and
dementia risk by mining the US FDA Adverse Event Reporting System
(FAERS) database. METHODS: We identified six PPI agents and adverse
reports of dementia based on FAERS database from 2004 to 2019. We
employed reporting odds ratio (ROR) and proportional reporting ratio
(PRR) to detect the signals of dementia relevant to PPIs. We also
analyzed characteristics of PPI reports, compared dementia events
between short- and long- duration PPIs treatment. RESULTS: We identified
2104 dementia cases with PPIs treatment. We did not detect significant
signals between PPIs and dementia, ROR = 0.99, 95%CI 0.94 - 1.03, PRR =
0.99, 95%CI 0.95 - 1.03, even in gastroesophageal reflux disease cases
ROR = 0.65, 95%CI 0.58 - 0.73, PRR = 0.67, 95%CI 0.60 - 0.74. No
significant differences of dementia events were detected between short-
and long- duration groups, the OR (95%CI) of the 6 months, 1 year, 3
years and 5 years comparison were 0.85 (0.68 - 1.06), 0.92 (0.71 -
1.18), 0.81 (0.57 - 1.15) and 0.79 (0.52 - 1.22), respectively.
CONCLUSIONS: Based on the current FAERS data mining, we discovered no
association between PPIs use and the risk of dementia.